Opinion|Videos|July 3, 2024
Improving Access for Patients Receiving CAR T-Cell Therapy
Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.
Advertisement
Episodes in this series
- Dr. Sharma/Dr. Krishnan: What strategies can help community doctors better understand the complications of CAR-T and how do we better coordinate with academic centers to refer back or and which complications can be managed in the community setting?
- How can community physicians be trained to recognize and manage CAR-T complications?
Advertisement
Related to this article
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5